Where does Tango Therapeutics's cash flow data come from?

Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Tango Therapeutics TNGX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$101.59M+22.0%	-$130.3M-28.1%	-$101.74M+5.9%	-$108.18M-85.8%
Depreciation and amortization	$2.28M-8.7%	$2.5M+3.5%	$2.42M+50.2%	$1.61M+84.4%
Stock-based compensation	$26.43M-8.5%	$28.9M+51.5%	$19.08M+34.1%	$14.23M+81.7%
Change in accounts payable	——	-$1.18M+30.6%	-$1.71M—	——
Change in other assets	$319K+809%	-$45K—	——	-$122K-188%
Other working capital changes	$77K—	——	——	$669K+363%
Change in deferred revenue	-$62.38M-108%	-$29.97M+4.9%	-$31.53M-87.0%	-$16.86M—
Non-cash operating lease expense	$3.96M+5.8%	$3.75M+3.9%	$3.61M+49.0%	$2.42M+126%
Net cash from operating activities	-$138.89M-5.6%	-$131.5M-11.5%	-$117.98M-8.2%	-$109.08M-83.2%
Capital expenditures	$1.05M+39.0%	$754K-50.6%	$1.53M-80.2%	$7.69M+319%
Net cash from investing activities	-$40.87M-147%	$86.13M—	——	——
Proceeds from issuance of common stock	——	——	——	——
Net cash from financing activities	$222.5M+367%	$47.66M-42.2%	$82.41M+5,003%	$1.62M—
Net increase (decrease) in cash	$42.75M+1,768%	$2.29M-60.9%	$5.85M+107%	-$85.74M—
Depreciation	$2.28M-8.7%	$2.5M+3.5%	$2.42M+50.2%	$1.61M+84.4%
Accounts payable	——	-$1.18M+30.6%	-$1.71M—	——
Increase Decrease In Accrued Expenses And Other Liabilities	——	$1.13M—	——	$7.63M+99.2%
Deferred revenue	-$62.38M-108%	-$29.97M+4.9%	-$31.53M-87.0%	-$16.86M—
Increase Decrease In Operating Lease Liabilities	-$3.03M-41.7%	-$2.14M+12.3%	-$2.44M-243%	$1.7M+259%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——
Operating lease right-of-use asset amortization	$3.96M+5.8%	$3.75M+3.9%	$3.61M+49.0%	$2.42M+126%
Other Noncash Income (Expense)	$77K—	——	——	$669K+363%
Payments Of Stock Issuance Costs	$36K—	——	——	$8K—
Proceeds From Contributed Capital	——	——	$689K—	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——
Operating Lease Liabilities From Obtaining Right Of Use Assets	——	$210K—	——	——
Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification	——	——	-$228K-176%	$300K-94.4%
Cash Paid For Leases	$5.86M+4.6%	$5.6M-4.7%	$5.88M+316%	$1.41M+177%
Free cash flow	-$139.93M-5.8%	-$132.26M-10.7%	-$119.51M-2.3%	-$116.77M-90.3%
Free cash flow	-$139.93M-5.8%	-$132.26M-10.7%	-$119.51M-2.3%	-$116.77M-90.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Tango Therapeutics's cash flow data come from?: Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.